Plixorafenib
Based on 20 publication(s) in Google Scholar
PLX8394 is a potent and selective BRaf inhibitor, with an IC50 of appr 5 nM for BRAFV600E.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.10%
- CAS. Nr.: 1393466-87-9
- Formel: C25H21F3N6O3S
- Molecular Weight:542.53
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
MAPK Compound Library
HY-L010
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Obesity Compound Library
HY-L087
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) Plixorafenib
More- Cancer Discov. 2018 Sep;8(9):1130-1141. [Abstract]
- Nat Commun. 2022 Jul 15;13(1):4109. [Abstract]
- Nat Commun. 2021 Mar 19;12(1):1747. [Abstract]
- Nat Commun. 2018 Nov 14;9(1):4775. [Abstract]
- Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31105-31113. [Abstract]
- Oncogene. 2023 Dec;42(49):3633-3647. [Abstract]
- EMBO Mol Med. 2021 May 7;13(5):e13466. [Abstract]
- Cell Syst. 2022 Oct 19;13(10):830-843.e3. [Abstract]
- Cell Syst. 2020 Nov 18;11(5):478-494.e9. [Abstract]
- Clin Sci (Lond). 2019 Apr 16;133(8):919-932. [Abstract]
- Sci Signal. 2025 Sep 2;18(902):eadw3231. [Abstract]
- Mol Cancer Ther. 2020 Aug;19(8):1736-1750. [Abstract]
- Biomolecules. 2021 Mar 30;11(4):518. [Abstract]
- Mol Cell Biol. 2016 Sep 26;36(20):2612-25. [Abstract]
- J Chem Eng Data. 2024 Jun 10.
- Research Square Preprint. 2024 Nov 26.
- bioRxiv. 2021 Apr 9.
- bioRxiv. 2020 Jul.
- bioRxiv. 2020 Mar.
- bioRxiv. 2019 Sep.
Customer Validation & Images
-
WB
Biologische Aktivität
|
BRafV600E 5 nM (IC50) |
PLX8394 potently inhibits phosphorylation of ERK1/2 in PRT #3 and PRT #4 cells at >25 nM and in addition to parental cells at 10 nM. PLX8394 effectively reduces cyclin D3 and cyclin D1, phosphorylation of retinoblastoma protein, and expression of cyclin A2 in parental cells and PRT #3 and PRT #4 cells. PLX8394 inhibits ERK1/2 phosphorylation and the growth of PLX4032-resistant cells harboring either a BRAF V600K/L505H double mutation or an transposon-induced, N-terminal truncated form of BRAF[1]. PLX8394 significantly impairs tumor cell growth and suppresses MAPK signaling in LA cell lines expressing either endogenous V600E or non-V600 mutant forms of BRAF[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 1393466-87-9
-
Appearance Solid
-
Molecular Weight 542.53
-
Formel C25H21F3N6O3S
-
Color White to light yellow
-
SMILES
O=C(C1=C(F)C(NS(=O)(N2CC[C@@H](F)C2)=O)=CC=C1F)C3=CNC4=C3C=C(C=N4)C5=CN=C(C6CC6)N=C5
-
Synonyms
PLX8394; FORE8394
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (20)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor. [Abstract]2018 Sep;8(9):1130-1141. PMID: 29880583
Plixorafenib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2018 Sep;8(9):1130-1141. [Abstract]
BRAF V600E or V600E/L514V are transiently transfected in SKBR3 for 24 hr. Then the cells are treated with 1 μM GW572016 for 1 hr, followed by treatment with DMSO or the RAF inhibitors indicated for 1 hr (the dose for PLX7904 is 1 μM).
-
Nat Commun
2022 Jul 15;13(1):4109. PMID: 35840569 -
Nat Commun
Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling. [Abstract]2021 Mar 19;12(1):1747. PMID: 33741929 -
Nat Commun
Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. [Abstract]2018 Nov 14;9(1):4775. PMID: 30429474 -
Proc Natl Acad Sci U S A
Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies. [Abstract]2020 Dec 8;117(49):31105-31113. PMID: 33229534 -
Oncogene
Inhibition of TGF-β signaling, invasion, and growth of cutaneous squamous cell carcinoma by PLX8394. [Abstract]2023 Dec;42(49):3633-3647. PMID: 37864034 -
EMBO Mol Med
CRISPR screens identify tumor-promoting genes conferring melanoma cell plasticity and resistance. [Abstract]2021 May 7;13(5):e13466. PMID: 33724679 -
Cell Syst
Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures. [Abstract]2022 Oct 19;13(10):830-843.e3. PMID: 36265469 -
Cell Syst
Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells. [Abstract]2020 Nov 18;11(5):478-494.e9. PMID: 33113355 -
Clin Sci (Lond)
A pan-RAF inhibitor LY3009120 inhibits necroptosis by preventing phosphorylation of RIPK1 and alleviates dextran sulfate sodium-induced colitis. [Abstract]2019 Apr 16;133(8):919-932. PMID: 30944150 -
Sci Signal
MAPK and mTORC1 signaling converge to drive cyclin D1 protein production to enable cell cycle reentry in melanoma persister cells. [Abstract]2025 Sep 2;18(902):eadw3231. PMID: 40892895 -
Mol Cancer Ther
A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells. [Abstract]2020 Aug;19(8):1736-1750. PMID: 32451331 -
Biomolecules
Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico. [Abstract]2021 Mar 30;11(4):518. PMID: 33808483 -
Mol Cell Biol
2016 Sep 26;36(20):2612-25. PMID: 27503857 -
-
-
-
-
-
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (184.32 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
For MTT assays, 2×103 cells are seeded in triplicate in 96 wells in their regular culture medium (containing PLX4720 for PRT lines). Next day, cells are washed twice with PBS and then the medium is replenished containing the indicated RAF inhibitor. Medium is changed 48 hours later and after a further 48 hours, 10 μL of 5 mg/mL MTT reagent is added to wells, and incubated for three hours. Formazan crystals are then solubilized overnight with a 1:10 dilution of 0.1 M glycine (pH 10.5) in DMSO. Wells are then analyzed at 450 nM in a Multiskan® Spectrum spectrophotometer. Results depicted are normalized to DMSO conditions and are a composite of three independent experiments. Error bars shown are representative of the standard error of mean (SEM).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
H1755 tumor xenografts are generated by injection of 5×106 cells in a 50/50 mixture for matrigel and PBS into 6- to 8-wk-old female NOD/SCID mice. Mice are randomized to treatment groups once tumors reach an average size of 150 mm3. H1755 cells are s.c. implanted and allowed to grow to appr 200 mm3 (4 wk after implantation). Mice are then treated with vehicle, PLX4032, or PLX8394 for 15 d. The vehicle for daily oral gavage is PEG 400 [20% (vol/vol)], tocopheryl polyethylene glycol succinate (TPGS) [5% (vol/vol)], water [75% (vol/vol)]. PLX8394 is dissolved in PEG 400 [20% (vol/vol)], TPGS [5% (vol/vol)], and water [75% (vol/vol)] and vortexed continuously throughout the dosing period. PLX8394 is given daily by oral gavage at a dose of 150 mg/kg/d.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (280 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Basile KJ, et al. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 2014 May;27(3):479-484. [Content Brief]
[2]. Okimoto RA, et al. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13456-13461 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8432 mL | 9.2161 mL | 18.4322 mL | 46.0804 mL |
| 5 mM | 0.3686 mL | 1.8432 mL | 3.6864 mL | 9.2161 mL | |
| 10 mM | 0.1843 mL | 0.9216 mL | 1.8432 mL | 4.6080 mL | |
| 15 mM | 0.1229 mL | 0.6144 mL | 1.2288 mL | 3.0720 mL | |
| 20 mM | 0.0922 mL | 0.4608 mL | 0.9216 mL | 2.3040 mL | |
| 25 mM | 0.0737 mL | 0.3686 mL | 0.7373 mL | 1.8432 mL | |
| 30 mM | 0.0614 mL | 0.3072 mL | 0.6144 mL | 1.5360 mL | |
| 40 mM | 0.0461 mL | 0.2304 mL | 0.4608 mL | 1.1520 mL | |
| 50 mM | 0.0369 mL | 0.1843 mL | 0.3686 mL | 0.9216 mL | |
| 60 mM | 0.0307 mL | 0.1536 mL | 0.3072 mL | 0.7680 mL | |
| 80 mM | 0.0230 mL | 0.1152 mL | 0.2304 mL | 0.5760 mL | |
| 100 mM | 0.0184 mL | 0.0922 mL | 0.1843 mL | 0.4608 mL |
Plixorafenib Related Classifications
HY-18972 Related Classifications
Powered by Bioz